Julia Mayerle
About
Julia Mayerle is a scholar working on Surgery, Oncology and Epidemiology.
According to data from OpenAlex, Julia Mayerle has authored 291 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Surgery, 139 papers in Oncology and 63 papers in Epidemiology. Recurrent topics in Julia Mayerle's work include Pancreatitis Pathology and Treatment (128 papers), Pancreatic and Hepatic Oncology Research (118 papers) and Liver Disease Diagnosis and Treatment (40 papers). Julia Mayerle is often cited by papers focused on Pancreatitis Pathology and Treatment (128 papers), Pancreatic and Hepatic Oncology Research (118 papers) and Liver Disease Diagnosis and Treatment (40 papers). Julia Mayerle collaborates with scholars based in Germany, United States and United Kingdom. Julia Mayerle's co-authors include Markus M. Lerch, Frank Ulrich Weiß, Matthias Sendler, Ali A. Aghdassi, Georg Beyer, Henry Völzke, Jens‐Peter Kühn, Ujjwal Mukund Mahajan, Georg Homuth and Claudia Nitsche and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Nature Communications.
In The Last Decade
Julia Mayerle
269 papers receiving 8.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Julia Mayerle Germany | 54 | 4.6k | 3.7k | 2.2k | 1.9k | 903 | 291 | 8.8k | ||
| Atsushi Masamune Japan | 58 | 5.0k 1.1× | 4.7k 1.3× | 3.1k 1.4× | 1.8k 1.0× | 1.9k 2.1× | 446 | 10.5k | ||
| Roland Andersson Sweden | 49 | 4.2k 0.9× | 4.0k 1.1× | 2.0k 0.9× | 1.1k 0.6× | 829 0.9× | 377 | 9.2k | ||
| Wolfram Trudo Knoefel Germany | 52 | 5.1k 1.1× | 4.1k 1.1× | 1.9k 0.9× | 2.5k 1.3× | 588 0.7× | 325 | 10.5k | ||
| Karl‐Walter Jauch Germany | 58 | 3.7k 0.8× | 4.2k 1.1× | 3.0k 1.4× | 1.3k 0.7× | 786 0.9× | 229 | 11.4k | ||
| Luís Bujanda Spain | 52 | 3.4k 0.7× | 2.5k 0.7× | 2.8k 1.3× | 1.5k 0.8× | 397 0.4× | 330 | 9.6k | ||
| Ugo Boggi Italy | 52 | 6.0k 1.3× | 3.5k 0.9× | 2.6k 1.2× | 1.3k 0.7× | 608 0.7× | 364 | 10.5k | ||
| Carmen C. Solórzano United States | 46 | 3.8k 0.8× | 2.2k 0.6× | 1.1k 0.5× | 1.1k 0.6× | 498 0.6× | 185 | 7.8k | ||
| Seiki Matsuno Japan | 47 | 4.1k 0.9× | 5.1k 1.4× | 2.1k 1.0× | 1.3k 0.7× | 601 0.7× | 278 | 8.8k | ||
| Tuomo J. Karttunen Finland | 51 | 3.1k 0.7× | 2.4k 0.6× | 2.0k 0.9× | 1.5k 0.8× | 1.4k 1.6× | 214 | 8.6k | ||
| Hirokazu Nagawa Japan | 58 | 3.4k 0.7× | 4.6k 1.3× | 3.8k 1.8× | 1.8k 1.0× | 1.4k 1.6× | 392 | 12.8k |
Countries citing papers authored by Julia Mayerle
Since
Specialization
Citations
This map shows the geographic impact of Julia Mayerle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Mayerle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Mayerle more than expected).
Fields of papers citing papers by Julia Mayerle
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julia Mayerle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Mayerle. The network helps show where Julia Mayerle may publish in the future.
Co-authorship network of co-authors of Julia Mayerle
This figure shows the co-authorship network connecting the top 25 collaborators of Julia Mayerle. A scholar is included among the top collaborators of Julia Mayerle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Mayerle. Julia Mayerle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Munker, Stefan, Najib Ben Khaled, Murat Fındık, et al.. (2025). Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis. Journal of Hepatocellular Carcinoma. Volume 12. 855–864.
2.
Weigl, Martin, Marion Subklewe, Michael von Bergwelt‐Baildon, et al.. (2025). Predicting work ability impairment in post COVID-19 patients: a machine learning model based on clinical parameters. Infection. 53(3). 1189–1197.
3.
Khaled, Najib Ben, Julia Schneider, Alexander Weich, et al.. (2025). Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort. Alimentary Pharmacology & Therapeutics. 61(11). 1755–1766.
4.
Allawadhi, Prince, Ujjwal Mukund Mahajan, Elisabetta Goni, et al.. (2025). Diagnostic accuracy and Patient Derived Organoid (PDO) yield of 19G vs 22G Franseen needles for EUS-Guided biopsy in solid pancreatic lesions: A prospective comparative study. Pancreatology. 25(8). 1442–1449.
5.
Goni, Elisabetta, Jens Vikse, Marco Lanzillotta, et al.. (2025). Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study. European Journal of Internal Medicine. 143. 106459–106459.
6.
Vielhauer, Jakob, Ujjwal Mukund Mahajan, Kristina Adorjan, et al.. (2024). Electronic data capture in resource-limited settings using the lightweight clinical data acquisition and recording system. Scientific Reports. 14(1). 19056–19056.
7.
Berger, Karin, Peter Buggisch, Julia Mayerle, et al.. (2024). 195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis. Annals of Oncology. 35. S87–S87.
8.
Piseddu, Ignazio, Michael Karin, Julia Schneider, et al.. (2024). 202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma. Annals of Oncology. 35. S89–S89.
9.
Goni, Elisabetta, Christian Schulz, Michał Żorniak, et al.. (2024). Severity and outcome of a first episode of idiopathic acute pancreatitis is not more severe than pancreatitis of other etiologies. Pancreatology. 24(6). 840–846.
10.
Zhou, Quan, Tobias Straub, Jörg Kleeff, et al.. (2024). Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes. International Journal of Oncology. 64(3).
11.
Heinemann, Volker, Laura Fischer, Frank Gieseler, et al.. (2023). SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group. Annals of Oncology. 34. S164–S164.
12.
Karch, Susanne, Johannes R. Bogner, Julia Mayerle, et al.. (2023). Substantial differences in perception of disease severity between post COVID-19 patients, internists, and psychiatrists or psychologists: the Health Perception Gap and its clinical implications. European Archives of Psychiatry and Clinical Neuroscience. 274(8). 2015–2024.
13.
Mahajan, Ujjwal Mukund, Christoph J. Auernhammer, Beata Kos‐Kudła, et al.. (2022). Impact of tumor size and location on endoscopic ultrasound-guided sampling of pancreatic neuroendocrine tumors: A recursive partitioning analysis. Pancreatology. 22(5). 644–650.
14.
Khaled, Najib Ben, Liangtao Ye, Sebastian A. Widholz, et al.. (2022). TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Cancers. 14(21). 5240–5240.
15.
Schwarze, Vincent, et al.. (2021). Tuberculous perihepatic abscess and neurosarcoidosis: report of 2 uncommon manifestations of 2 common granulomatous diseases in 1 patient. Zeitschrift für Gastroenterologie. 59(1). 50–55.
16.
Marschner, Sebastian, Stefanie Corradini, R. Zacharias, et al.. (2020). SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine. Radiation Oncology. 15(1). 165–165.
17.
Zádori, Noémi, Noémi Gede, Andrea Szentesi, et al.. (2019). EarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial): Protocol of an open-label, multicenter, adaptive randomized clinical trial. Pancreatology. 20(3). 369–376.
18.
Schwaiger, Theresa, Michael R. Knittler, Christian Grund, et al.. (2017). Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity. International Journal of Cancer. 141(12). 2505–2516.
19.
Lobo, Víctor J. Sánchez‐Arévalo, Matthias Sendler, Antonio Salas, et al.. (2014). Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice. Gut. 64(6). 937–947.
20.
Teich, Niels, Ali A. Aghdassi, Julia Fischer, et al.. (2010). Optimal Timing of Oral Refeeding in Mild Acute Pancreatitis. Pancreas. 39(7). 1088–1092.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Atsushi Masamune Breakdown of academic impact, for papers by Roland Andersson Breakdown of academic impact, for papers by Wolfram Trudo Knoefel Breakdown of academic impact, for papers by Karl‐Walter Jauch Breakdown of academic impact, for papers by Luís Bujanda Breakdown of academic impact, for papers by Ugo Boggi Breakdown of academic impact, for papers by Carmen C. Solórzano Breakdown of academic impact, for papers by Seiki Matsuno Breakdown of academic impact, for papers by Tuomo J. Karttunen Breakdown of academic impact, for papers by Hirokazu Nagawa